This is the department of error for an article published in the Lancet in 2025. The article, entitled "Spironolactone in chronic hemodialysis patients at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicenter, double-blind, randomized, placebo-controlled trial and updated meta-analysis," was written by Rossignol P, Zannad F, Massy Z, and colleagues. The article misstated the name of Maud François in the list of ALCHEMIST study groups and in the appendix. The correction was made in the online version from January 29, 2026.